SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier
Material Name: Clindamycin Phosphate Vaginal Suppositories
Trade Name: CLEOCIN; DALACIN; SOBELIN
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet
Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture
GHS - Classification
Skin Sensitization: Category 1

Label Elements
Signal Word: Warning
Hazard Statements: H317 - May cause an allergic skin reaction

Precautionary Statements:
P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P272 - Contaminated work clothing must not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P302+P352 - IF ON SKIN: Wash with plenty of soap and water
P333+P313 - If skin irritation or rash occurs: Get medical advice/attention
P321 - Specific treatment (see supplemental first aid instructions on this label)
P363 - Wash contaminated clothing before reuse
P501 - Dispose of contents/container in accordance with all local and national regulations
Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clindamycin Phosphate</td>
<td>24729-96-2</td>
<td>246-433-0</td>
<td>Acute Tox.4 (H302)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Eye Irrit.2A (H319)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Skin Irrit.3 (H316)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Skin Sens.1 (H317)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrogenated coco-glycerides</td>
<td>91744-42-2</td>
<td>294-604-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

PZ00424
SAFETY DATA SHEET

Material Name: Clindamycin Phosphate Vaginal Suppositories
Revision date: 31-Jul-2018
Page 3 of 7
Version: 3.2

Symptoms and Effects of Exposure:
For information on potential signs and symptoms of exposure, see Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters
During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid contact with eyes. Avoid prolonged or repeated contact with skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Clindamycin Phosphate
Pfizer OEL TWA-8 Hr: 100µg/m^3

Exposure Controls
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Not required for the normal use of this product. Individuals with known sensitivity should wear protective gloves to avoid skin contact.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities. Individuals with known sensitivity should wear long sleeves to avoid skin contact. Wash hands and arms thoroughly after handling this material.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Suppository

Odor: No data available.

Molecular Formula: Mixture

Solvent Solubility: No data available

Water Solubility: No data available

pH: No data available.

Melting/Freezing Point (°C): No data available

Boiling Point (°C): No data available

Partition Coefficient: (Method, pH, Endpoint, Value)

Hydrogenated coco-glycerides

Clindamycin Phosphate

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable at normal conditions

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Keep away from excessive heat and flames.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
10. STABILITY AND REACTIVITY

Hazardous Decomposition
No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the active ingredient.

Short Term: May be harmful if swallowed. May cause eye irritation (based on components). May cause mild skin irritation (based on animal data). An Occupational Exposure Limit has been established for one or more of the ingredients (see Section 8).

Known Clinical Effects: Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused sore throat, fever, gastrointestinal disturbances, abnormal liver function tests, kidney dysfunction. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur.

Acute Toxicity: (Species, Route, End Point, Dose)

Clindamycin Phosphate

Rat Oral LD 50 1832 mg/kg
Rat Para-periosteal LD 50 321mg/kg
Rat Intraperitoneal LD 50 745mg/kg
Mouse Oral LD 50 2359mg/kg
Mouse Intravenous LD 50 820mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Clindamycin Phosphate

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Clindamycin Phosphate

6 Month(s) Rat Oral 600 mg/kg/day NOAEL No effects at maximum dose
6 Month(s) Dog Oral 600 mg/kg/day NOAEL Gastrointestinal system

Reproductive & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Clindamycin Phosphate

Prenatal & Postnatal Development Rat Subcutaneous 250 mg/kg NOAEL Not teratogenic
Prenatal & Postnatal Development Rat Oral 300 mg/kg/day NOAEL Not Teratogenic
Prenatal & Postnatal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic
Prenatal & Postnatal Development Rabbit Subcutaneous 5 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity
Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Phosphate

Bacterial Mutagenicity (Ames) Salmonella Negative
In Vitro Micronucleus Rat Negative
11. TOXICOLOGICAL INFORMATION

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Clindamycin Phosphate

CERCLA/SARA 313 Emission reporting Not Listed

California Proposition 65 Not Listed
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>EU EINECS/ELINCS List</th>
<th>246-433-0</th>
</tr>
</thead>
</table>

Hydrogenated coco-glycerides
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Australia (AICS): Present
- EU EINECS/ELINCS List: 294-604-3

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3
- Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
- Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation
- Skin corrosion/irritation-Cat.3; H316 - Causes mild skin irritation
- Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 2 - Hazard Identification.

Revision date: 31-Jul-2018
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet